Companies · SANA
Sana Biotechnology
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Aug 10, 2026
Sana Biotechnology targets dual IND filings and first-in-human data for SC451 and SG293 by year-end 2026, backed by $160.5M cash and a $25M Mayo Clinic equity anchor.
Sana Biotechnology's Q2 2026 filing signals a critical clinical inflection point: the company expects to file an IND and begin a Phase 1/2 trial for SC451 (HIP-modified iPSC-derived islet cell therapy) and generate first-in-human data for SG293 (CD8-targeted fusosome) in non-Hodgkin lymphoma as early as this year, with management guiding to 'valuable insight into the clinical profiles and potential of both SC451 and SG293 over the next 6-9 months.' The UP421 investigator-sponsored trial published 14-month durability data in the New England Journal of Medicine, demonstrating continued C-peptide production and immune evasion without immunosuppression — the strongest external validation of HIP technology to date. With $160.5M in cash (including $93.3M raised in Q2 via ATM and the $25M Mayo Clinic equity investment) and non-GAAP operating cash burn of $69.3M for the first half, runway extends only into mid-2027, making near-term clinical proof-of-concept data existential for the company's capital access.
Tone: cautiousEmployees
142
Founded
2018
Headquarters
Seattle, WA
Profile
SANA 10-K Item 1 · Mar 3, 2026Sana Biotechnology is a clinical-stage cell engineering company developing ex vivo and in vivo engineered cell therapies for type 1 diabetes, B cell malignancies, and B cell mediated autoimmune diseases. Its two lead programs are SC451, a hypoimmune iPSC-derived pancreatic islet cell therapy targeting T1D, and SG293, an in vivo CD8-targeted CAR T fusosome for B cell cancers and autoimmune disease. The company's proprietary hypoimmune (HIP) platform enables allogeneic cell transplantation without immunosuppression.
Read filing description ↓ Collapse description ↑
We were founded on the belief that engineered cells will be one of the most important transformations in medicine over the next several decades. The burden of diseases that can be addressed at their root cause through engineered cells is significant. We view engineered cells as having the potential to be as therapeutically disruptive as biologic drugs to clinical practice, enabling us to repair cells in the body when possible and replace them when needed. We have developed ex vivo and in vivo cell engineering platforms to revolutionize treatment across a broad array of therapeutic areas with unmet treatment needs, including type 1 diabetes, oncology, and B cell mediated autoimmune diseases. For our ex vivo platform, we have made focused investments in our hypoimmune platform technology, which we refer to as our HIP technology, with the twin goals of engineering allogeneic cells that can 'hide' from the patient's immune system to overcome the fundamental challenge of immune rejection and cell persistence and that we can manufacture at scale. A successful therapeutic requires cells that can engraft, function, and persist in the body, and we believe our approach can unlock a wave of disruptive therapeutics, starting in type 1 diabetes. For in vivo therapies that aim to repair or control genes in the body, a successful product candidate requires both gene modification and in vivo delivery of the therapeutic payload. Our initial focus is on cell-specific delivery of genetic payloads, known as chimeric antigen receptors (CARs), to a patient's T cells, resulting in the generation and proliferation of CAR T cells, which have been shown to deplete a patient's disease-causing B cells. We are currently focused on advancing two distinct therapeutics, each of which leverages one of these platform technologies. SC451 is our HIP-edited product candidate for the treatment of type 1 diabetes. SG293 is our in vivo CAR T product candidate for the treatment of B cell malignancies and B cell mediated autoimmune diseases. We retain worldwide rights to each of these product candidates.
Primary products
- SC451 (HIP-modified iPSC-derived pancreatic islet cell therapy)
- SG293 (CD8-targeted fusosome in vivo CAR T)
- UP421 (HIP-modified allogeneic primary islet cell therapy)
End markets
Geographies
Named customers
Named competitors
“Among companies pursuing ex vivo and in vivo cell engineering, we believe we are substantially differentiated by our robust intellectual property portfolio, extensive research, rigorous and objective approach, and multidisciplinary capabilities.” Competitive position, as stated in the filing
The rest of SANA is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.